Selected article for: "available cell line and cell line"
Author: Kain, Taylor; Lindsay, Patrick J.; Adhikari, Neill K.J.; Arabi, Yaseen M.; Van Kerkhove, Maria D.; Fowler, Robert A.
Title: Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome
  • Cord-id: a9q6iotm
  • Document date: 2020_6_25
    • ID: a9q6iotm
    Snippet: Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eli
    Document: Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.

    Search related documents:
    Co phrase search for related documents
    • logistic regression and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
    • logistic regression and low evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • logistic regression and low evidence quality: 1
    • logistic regression and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • logistic regression and low quality evidence: 1
    • logistic regression and macrolide therapy: 1
    • logistic regression and macrolide therapy association: 1
    • lopinavir ritonavir and low evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • lopinavir ritonavir and low evidence quality: 1, 2, 3, 4, 5
    • lopinavir ritonavir and low quality: 1, 2, 3, 4, 5
    • lopinavir ritonavir and low quality evidence: 1, 2, 3, 4, 5
    • low evidence and macrolide therapy: 1
    • low evidence quality and macrolide therapy: 1